A phase II trial shows that pembrolizumab and bevacizumab yield a 54.1% intracranial response rate and a median overall ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally ...

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

Interim analysis findings showed the perioperative treatment group demonstrated a statistically significant improvement in event-free survival compared with adjuvant radiotherapy, with or without ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Participants (median age, 58.5 years) received intravenous pembrolizumab (200 mg) every 21 days for up to 2 years or until disease progression, with a maximum of 35 cycles. Tumour assessments ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific ...